Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to...

Area of Science:

• Pharmacology and Drug Development
• Clinical Trial Design
• Oncology Therapeutics

Background:

• Poor dose optimization in drug development leads to patient toxicity, reduced treatment effectiveness, and challenges in combination therapy.
• Integrates dose optimization strategies and statistical principles into premarketing drug development.

Purpose of the Study:

• To review US Food and Drug Administration (FDA) approvals (2019-2021) for oncologic indications.
• To determine the proportion of drugs recommended at maximum tolerated dose (MTD) or maximal administered dose (MAD).
• To characterize the use of randomized dose evaluations and dose modifications in oncology drug development.

Main Methods:

• Analysis of FDA initial approvals for small molecules and antibody-drug conjugates (2019-2021) in oncology.
• Examination of dose selection, use of randomized dose evaluations, and frequency of dose modifications.
• Identification of case examples illustrating dose optimization principles.

Main Results:

• A review of recent FDA oncology approvals reveals that dose optimization through randomized dose evaluation is not routinely conducted.
• Identified key principles for premarket dose optimization and provided examples from recent FDA approvals.
• Highlighted the importance of investigating dose- and exposure-response relationships and utilizing randomized dose trials.

Conclusions:

• Dose optimization is essential for ensuring cancer therapies maximize efficacy while minimizing toxicity.
• Despite some progress, routine implementation of randomized dose evaluations in oncology trials remains a challenge.
• Effective dose optimization strategies are critical for improving patient quality of life and treatment outcomes.